In October 2019, the American pharmaceutical company Biogen stated intention to apply to the US Food and Drug Administration (FDA) for the candidate drug aducanumab to be licenced as a therapeutic agent for the treatment of Alzheimer's disease (AD). If approved, aducanumab would become the first new medication licenced specifically for the treatment of AD in the past decade; and approval in the US may be a precipitant for approval elsewhere
In this Oliver C. Schroeder, Jr. Scholar-in-Residence Lecture, Michael Carome, MD, director of Publi...
Alzheimer's disease is a major cause of morbidity and mortality. Currently, there are no disease-mod...
In 2021, the US Food and Drug Administration (FDA) granted approval to aducanumab, an antiamyloid an...
DeclarationsFunding The preparation of this review was not supported by any external funding.Authors...
The US FDA approved Aducanumab in June 2021 as the first Alzheimer's disease (AD) drug under its acc...
Alzheimer’s disease (AD) is the most common form of dementia affecting millions of individuals, incl...
Alzheimer’s disease (AD) is the most common cause for dementia worldwide. Until recently, all approv...
As our collective biomedical knowledge increases, we find ourselves increasingly reliant on the expe...
Alzheimer's disease is the most common form of dementia, affecting millions of people, including fam...
•Controversial registration of aducanumab for Alzheimer's Disease •Aducanumab is the subject of pos...
On 7 June, the FDA approved aducanumab, the first new drug for Alzheimer’s disease in almost 20 year...
The controversial approval in June 2021 by the Food and Drug Administration (FDA) of aducanumab (mar...
Alzheimer’s disease (AD) is the main cause of disability in people older than 60 years. More than 1 ...
Aducanumab, a human monoclonal antibody, was approved in June of 2021 as the first disease-modifying...
Aducanumab, a human monoclonal antibody, was approved in June of 2021 as the first disease-modifying...
In this Oliver C. Schroeder, Jr. Scholar-in-Residence Lecture, Michael Carome, MD, director of Publi...
Alzheimer's disease is a major cause of morbidity and mortality. Currently, there are no disease-mod...
In 2021, the US Food and Drug Administration (FDA) granted approval to aducanumab, an antiamyloid an...
DeclarationsFunding The preparation of this review was not supported by any external funding.Authors...
The US FDA approved Aducanumab in June 2021 as the first Alzheimer's disease (AD) drug under its acc...
Alzheimer’s disease (AD) is the most common form of dementia affecting millions of individuals, incl...
Alzheimer’s disease (AD) is the most common cause for dementia worldwide. Until recently, all approv...
As our collective biomedical knowledge increases, we find ourselves increasingly reliant on the expe...
Alzheimer's disease is the most common form of dementia, affecting millions of people, including fam...
•Controversial registration of aducanumab for Alzheimer's Disease •Aducanumab is the subject of pos...
On 7 June, the FDA approved aducanumab, the first new drug for Alzheimer’s disease in almost 20 year...
The controversial approval in June 2021 by the Food and Drug Administration (FDA) of aducanumab (mar...
Alzheimer’s disease (AD) is the main cause of disability in people older than 60 years. More than 1 ...
Aducanumab, a human monoclonal antibody, was approved in June of 2021 as the first disease-modifying...
Aducanumab, a human monoclonal antibody, was approved in June of 2021 as the first disease-modifying...
In this Oliver C. Schroeder, Jr. Scholar-in-Residence Lecture, Michael Carome, MD, director of Publi...
Alzheimer's disease is a major cause of morbidity and mortality. Currently, there are no disease-mod...
In 2021, the US Food and Drug Administration (FDA) granted approval to aducanumab, an antiamyloid an...